Evidence map›Paper›PMID 32299493›Full record

ArticleBMC research notes2020

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.

Andra Tilgase, Lita Grīne, Ilze Blāķe, Mārtiņs Borodušķis, Agnija Rasa, Pēteris Alberts

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Andra TilgaseRigvir, Atlasa iela 7C, LV-1026, Riga, Latvia. andra.tilgase@rigvir.com.
Lita GrīneUniversity of Latvia, Jelgavas iela 1, LV-1004, Riga, Latvia.
Ilze BlāķeUniversity of Latvia, Jelgavas iela 1, LV-1004, Riga, Latvia.
Mārtiņs BorodušķisUniversity of Latvia, Jelgavas iela 1, LV-1004, Riga, Latvia.
Agnija RasaRigvir, Atlasa iela 7C, LV-1026, Riga, Latvia.
Pēteris AlbertsRigvir, Atlasa iela 7C, LV-1026, Riga, Latvia.
University of Latvia · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUveal melanoma is a rare intraocular malignancy. Half of the patients diagnosed will develop metastases within 10 to 30 years, most commonly in the liver. Although there has been a significant development in the treatment of melanoma, no effective treatment to prevent or treat metastases of uveal melanoma is available. Oncolytic viruses are now being studied for various types of cancers and show promising results. Preclinical results show cytolytic activity of enteric cytopathic human orphan virus type 7 (ECHO-7) strain Rigvir in human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma and pancreas adenocarcinoma cell lines. The aim of this study was to test the possible cytolytic activity in human uveal melanoma cell lines.

resultsThe results suggest cytolytic activity of oncolytic ECHO-7 virus strain Rigvir in MP41, 92-1 and Mel-202 cell lines.

Indexed as

Oncolytic VirotherapyOncolytic VirusesCell Line, TumorHumansMelanomaUveal MelanomaUveal NeoplasmsECHO-7Oncolytic virusRigvirUveal melanoma

Identifiers

PMID32299493
PMCPMC7164219
OpenAlexW3016683052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.